Vor Biopharma Inc (VOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vor Biopharma Inc (VOR) has a cash flow conversion efficiency ratio of 0.139x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.80 Million) by net assets ($-164.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vor Biopharma Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Vor Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read VOR total debt and obligations for a breakdown of total debt and financial obligations.
Vor Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vor Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samsung Fire And Marine Ins Pref
KO:000815
|
0.068x |
|
Wuhan Hiteck Biological Pharma Co Ltd
SHE:300683
|
-0.008x |
|
HELLOFRESH UNSP.ADS/025
F:HFG0
|
N/A |
|
Beijing Tianyishangjia New Material Corp Ltd
SHG:688033
|
-0.018x |
|
Nufarm Ltd
AU:NUF
|
0.295x |
|
Sok Marketler Ticaret As
IS:SOKM
|
0.170x |
|
South Plains Financial Inc
NASDAQ:SPFI
|
0.049x |
|
Formosa International Hotels Corp
TW:2707
|
0.034x |
Annual Cash Flow Conversion Efficiency for Vor Biopharma Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Vor Biopharma Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Vor Biopharma Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-164.31 Million | $-142.71 Million | 0.869x | +184.24% |
| 2024-12-31 | $96.66 Million | $-99.66 Million | -1.031x | -54.94% |
| 2023-12-31 | $150.72 Million | $-100.29 Million | -0.665x | -95.85% |
| 2022-12-31 | $250.61 Million | $-85.14 Million | -0.340x | -6.26% |
| 2021-12-31 | $216.26 Million | $-69.14 Million | -0.320x | +57.47% |
| 2020-12-31 | $48.27 Million | $-36.29 Million | -0.752x | +41.71% |
| 2019-12-31 | $7.64 Million | $-9.86 Million | -1.290x | -428.03% |
| 2018-12-31 | $-6.77 Million | $-2.66 Million | 0.393x | -- |
About Vor Biopharma Inc
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML… Read more